Goldman Sachs Group Inc Catalyst Pharmaceuticals, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,472,253 shares of CPRX stock, worth $33.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,472,253
Previous 1,088,131
35.3%
Holding current value
$33.5 Million
Previous $16.9 Million
73.65%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding CPRX
# of Institutions
328Shares Held
94.1MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$426 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$183 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$142 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$130 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$68.8 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.34B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...